Abstract:Objectives: Chemoresistance development represents a major obstacle to the successful treatment of colorectal cancer (CRC). The aim of this study was to elucidate the mechanism by which miR-506 reverses oxaliplatin chemoresistance in CRC. Methods: In this study, miR-506 levels were measured in 74 patients with colon cancer via quantitative real-time polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH). We subsequently analysed the relationship between miR-506 expression and CRC patient survival via the Kaplan-Meier method. MTT assay demonstrated the fractional survival rates and cell viability of HCT116-OxR, HCT116-OxR-miR-Ctrl and HCT116-OxR-miR-506 cells treated with oxaliplatin at different concentrations. Cell proliferation and apoptosis were assessed via flow cytometry (FCM) analysis and apoptosis assay. MDR1 mRNA expression and P-gp protein expression were assessed via qRT-PCR and Western blotting (WB) respectively. Immunofluorescence (IF) staining demonstrated P-gp expression in HCT116-OxR and HCT116-OxR-miR-506 cells. qRT-PCR and WB were used to detect Wnt/beta-catenin pathway activity after miR-506 overexpression. Results: In the present study, in ISH and qRT-PCR results demonstrated that miR-506 is weakly expressed in chemoresistant CRC tissues. The low miR-506 expression group exhibited lower 5-year OS and lower 5-year RFS than the high miR-506 expression group. miR-506 overexpression inhibited cell growth and increased oxaliplatin-induced cell apoptosis in HCT116-OxR cells, as shown via FCM and apoptosis assay. We subsequently noted low MDR1/P-gp expression in HCT116-OxR-miR-506 cells via qRT-PCR, WB and IF. Lastly, we demonstrated low MDR1/P-gp expression in HCT116-OxR-miR--506 cells via inhibition of the Wnt/beta-catenin by WB, MTT and FCM analysis. Conclusion: Taken together, the findings of our study demonstrate that miR-506 overexpression in HCT116-OxR cells enhances oxaliplatin sensitivity by inhibiting MDR1/P-gp expression via down-regulation of the Wnt/beta-catenin pathway and thus provide a rationale for the development of miRNA-based strategies to reverse oxaliplatin resistance in CRC cells.

MicroRNA-504 Modulates Osteosarcoma Cell Chemoresistance to Cisplatin by Targeting P53

The Down-Regulation of MicroRNA-497 Contributes to Cell Growth and Cisplatin Resistance Through PI3K/Akt Pathway in Osteosarcoma

Mir-214 Modulates Cisplatin Sensitivity of Osteosarcoma Cells Through Regulation of Anaerobic Glycolysis.

Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85

miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.

MiR-138 Acts As a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells

MicroRNA-22 Inhibits the Proliferation and Migration, and Increases the Cisplatin Sensitivity, of Osteosarcoma Cells

Mir-504 Promotes Tumour Growth and Metastasis in Human Osteosarcoma by Targeting TP53INP1

Mir-509-3p Promotes Cisplatin-Induced Apoptosis in Ovarian Cancer Cells Through the Regulation of Anti-Apoptotic Genes.

A Chemotherapy-Driven Increase in Mcl-1 Mediates the Effect of miR-375 on Cisplatin Resistance in Osteosarcoma Cells.

MiR-125b Functions As a Tumor Suppressor and Enhances Chemosensitivity to Cisplatin in Osteosarcoma.

Mir-141-3p Promotes the Cisplatin Sensitivity of Osteosarcoma Cell Through Targeting the Glutaminase [Gls]-Mediated Glutamine Metabolism.

Mir-506: a Regulator of Chemo-Sensitivity Through Suppression of the RAD51-homologous Recombination Axis

Mir-503 Regulates the Resistance of Non-Small Cell Lung Cancer Cells to Cisplatin by Targeting Bcl-2.

MicroRNA-199a-5p Inhibits Cisplatin-Induced Drug Resistance Via Inhibition of Autophagy in Osteosarcoma Cells.

miR-1293 suppresses osteosarcoma progression by modulating drug sensitivity in response to cisplatin treatment

Mir-503-5p Confers Drug Resistance by Targeting PUMA in Colorectal Carcinoma

MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/fl-catenin in serous ovarian cancers

miR-197-3p Promotes Osteosarcoma Stemness and Chemoresistance by Inhibiting SPOPL

MiR-503 Regulates Cisplatin Resistance of Human Gastric Cancer Cell Lines by Targeting IGF1R and BCL2.

Elevated Mir-216B Enhances Cisplatin-Induced Apoptosis in Osteosarcoma by Downregulating JMJD2C and Regulating HIF-1α/HES1 Signaling Axis